Call for Abstract
18th World Congress on Biomarkers, Cancer Therapy & Clinical Research , will be organized around the theme “Latest discoveries and innovations in the field of Biomarkers & Clinical Research”
Biomarkers 2023 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biomarkers 2023
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Clinical research biomarkers which are used for clinical purposes are known as clinical biomarkers. Clinical biomarkers provide active and influential way to understanding the scope of many diseases and epidemiology, random clinical trials, screening for drugs or disease diagnosis and prognosis. It is defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors that can extend the basic information about the underlying pathogenesis of diseases. The main researches in clinical biomarkers are done in the fields of drug discovery, pharmacogenomics, oncology, and disease diagnostics. Classes of Biomarkers in Clinical trials are segmented into Safety biomarkers & Efficacy biomarkers.
A key fixing in fruitful business is self-learning. Biomarkers-2023 plans to unite all current and growing bio-business people to share encounters and present new developments and difficulties inside the malignant growth network. Every year, over a million organizations work on the planet with about 5–10 of them being named high innovation organizations. Transforming thoughts into business adventures is precarious and the open door acknowledgment step is basic in new pursuit manifestations. This gestalt in the business visionary's view of the connection between the creation and last item is refined into a plan of action that depicts how the endeavor will profit or give a fitting come back to the potential financial specialists. Disease science is perplexing and quickly changing and requires specific information to comprehend the estimation of the advancement and its aggressive position in the business. This multi -day network wide gathering will be a very intelligent discussion which will get specialists zones extending from Biomarkers to flagging pathways to novel helpful ways to deal with the logical centre point.
Biomarkers and diagnostics play a crucial role in the outcomes and findings in clinical settings to enhance the quality of human health. Translational biomarkers and diagnostics can be applied in both preclinical and clinical setting. It should aim to translate the findings in fundamental research into medical practice and meaningful health outcomes. The characteristics for acceptable translational biomarkers and the various approaches to their selections including the latest trends and developments in translational biomarkers and diagnostics shall be discussed in this session. This session also discusses and reviews methods and requirements for qualification of translational biomarkers.
This biomarker conference throws light on the use of biomarkers in drug development which has emphasised the use of biomarkers as surrogate end points for effectiveness. Biomarkers enhances the understanding of the mechanism of action, enables the assessment of target engagement, facilitates early proof of dose focusing and increases the efficiency of early clinical development with improved quality of decision making, these concepts help in the drug discovery and development process.
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to presence of cancer. Genetic, epigenetic, proteomic, glycolic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. While some cancer biomarkers can be used to predict how aggressively your cancer will grow, and are therefore useful for assessing your prognosis, the most promising use of biomarkers today is to identify which therapies a patient’s cancer may or may not respond to.
Among hundreds of thousands of cancer biomarkers have been discovered, only few of them have been approved during the past two decades by the FDA for monitoring response, surveillance, or recurrence of cancer. To be a clinically applicable and reliable biomarker, it must be of value for informing clinical decision-making to improve the patient outcome. Initially, CB have to distinguish between people with cancer and those without. In fact, many biomarkers do not achieve beyond this point because the investigators are either unable to develop robust, accurate assay methods, or this biomarker lacks sufficient sensitivity and/or specificity. Actually, there was very low rate (0.1%) of successful clinical translation of biomarker. Developing new cancer biomarkers has been formulated in stepwise manner. About 15 years ago, Hammond and Taube proposed an approach for CB development starting from discovering the marker, developing an assay method for assessment, analyzing its clinical potential preliminarily, standardization of its assay, and finally validation of such biomarker for clinical use.
Cardiovascular disease (CVD) remains the leading cause of death globally. The identification of traditional risk factors such as age, hypercholesterolemia, hypertension, diabetes mellitus, and smoking has improved primary prevention of CVD. Cardiac markers are measured biomarkers to assess cardiac function. They are often discussed in the context of myocardial infarction, but other conditions can lead to an elevation in the level of the cardiac marker. Cardiac biomarkers are elements that are released into the blood when the heart is damaged or strained. A cardiac marker is used in the identification and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS). These markers include enzymes, hormones and proteins. Cardiac biomarkers have evolved as essential tools in cardiology in the last 50 years, that is, for primary and secondary prevention, the diagnosis and treatment of acute myocardial infarction (AMI), and the diagnosis and stratification of the risk of heart failure.
In spite of all the advances in neurology, there are serious deficiencies in our understanding of the pathomechanism of several neurological disorders as well as our ability to diagnose and treat these disorders. Biotechnologies are being increasingly applied in neurology to address some of these deficiencies. Novel biomarker identification for neurological disorders will address the current shortcomings in their diagnosis and therapeutics.
The clinical use of biomarkers to survey the impact of safe based malignancy treatments is imperative for a few reasons. To start with, invulnerable based medicines, for example, immunizations, are frequently intended to inspire a particular reaction so the estimation of that reaction could be a marker of item (e.g., antibody) strength. Also, as safe based treatments are tried before in the restorative pathway (e.g., in the adjuvant setting), biomarkers of reaction turn out to be progressively imperative as potential endpoints of clinical preliminaries. At long last, clinically qualified biomarkers are required with the goal that new immunotherapies can be quickly and effectively tried and meant clinical practice.
Biomarkers focusing on two major areas of investigation: the early detection and prognosis. Early diagnosis and Prognostic Research encompasses the research addressing studies on the evaluation of medical tests, markers, prediction models and decision tools. Early diagnosis of cancer generally increases the chances for successful treatment by focusing on detecting symptomatic patients as early as possible. Delays in accessing cancer care are common with late-stage presentation, particularly in lower resource settings and vulnerable populations. The consequences of delayed or inaccessible cancer care are lower likelihood of survival, greater morbidity of treatment and higher costs of care, resulting in avoidable deaths and disability from cancer. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage and is therefore an important public health strategy in all settings.
Biomarkers plan an important role in various neurological and cardiovascular diseases. The diseases which are incurable from ages are being offered a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics and imaging technologies. Biomarkers are used in many other non-cancerous diseases.
Identification and validation of discovered gene or protein-based, network or dynamic network biomarkers with human diseases, patient phenotypes, or clinical applications, and accelerate the development of human disease-specific biomarkers for the early diagnosis, monitoring, evaluation, and prediction of diseases. Conditions including cancers, cardiovascular and metabolic diseases will be the focus of study. This section will promote the innovation and development of disease-specific biomarkers by integrating multidisciplinary aspects of science.
The biomarker congress focuses on the biomarker validation which is an open-ended process with open-ended evidentiary standards, where every potential application of the biomarker needs to be supported by independent studies and datasets. One aspect that has created a revolution in the concept of biomarker research and development is the Next Generation Sequencing which is versatile analysis tool for medical and biological research. Next Generation Sequencing technology refers to one high-throughput DNA sequencing method. In a single experiment, it can determine the sequence of the target gene or full genome with a total size of larger than millions of base pairs. Sequencing thousands of genes or even genomes in one experiment is consequently made possible using this NGS technology.
Genomics and Clinical development promise the development of biomarkers to a state to predict the risk of individual disease that allows early detection of the disease and improves diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements that can be used to predict the risk of diseases, to allow early detection of diseases, to improve the selection of treatment and to monitor the outcome of therapeutic interventions. The main objective of the Human Genome Project was the identification and development of such biomarkers for "personalized, preventive and predictive medicine”. This clinical conference focuses on biomarkers incorporating in the gene level into earlier stages of the clinical trials which help to separate the patients and help in the development of the biomarker and in case of clinical development this incorporation serves in multiple ways from guiding dose selection to selecting the mode of action to providing the strategy to know about to whom the a particular biomarker can be used.
Biomedical Engineering is the science of application of engineering principles to the fields of biology and health care. Bioengineers work with doctors, therapists and researchers to implement systems, equipment and devices in order to solve clinical problems which focus on the advances that improve human health and health care at all levels. Clinical engineering is a special field within Biomedical engineering responsible primarily for applying and implementing medical technology to optimize healthcare delivery.
Biomarker discovery requires high confidence identification of biomarker candidates with simultaneous quantitation information to indicate which proteins are changing to a statistically relevant degree in response to disease. Because of normal clinical or biological variability, candidate biomarkers identified in the discovery stage need to be validated across a large number of samples. The challenge is to develop a fast, targeted analysis method capable of analyzing as many identified candidates as possible in minimally hundreds and potentially even thousands of samples.
Biomarkers have been classified based on the epidemiological investigations exposure to disease & biomarkers of disease which are also used in the investigation of the natural history and prognosis of a disease. In addition to the factors between exposure and disease, biomarkers have the potential to identify the earliest events in the natural history, reducing the rate of misclassification of both disease and exposure, leads to increase potential mechanisms related to the disease pathogenesis, accounting for some of the variability and effect modification of risk prediction. These epidemiological investigations are one of the reasons behind biomarkers to improve validity while reducing bias in the measurement of exposures (or risk factors) for neurological disease.
In clinical trials using imaging, biomarkers and response criteria are used to assess the tumor evolution with therapy. Imaging biomarkers are often root contributors to a clinical trial’s endpoints, but they are not the same. Diagnostic tests and the biological biomarker (biomarkers) they measure are often classified based on the circumstances under which they are used. Biomarkers provide information about a patient at virtually every stage of care. They can help doctors evaluate the likelihood that a patient will develop a disease, diagnose a disorder, evaluate the severity of a disorder and/or its likely progression, determine optimal treatment strategies and monitor response to treatment.